Arcutis Biotherapeutics Inc [NASDAQ: ARQT] price surged by 27.04 percent to reach at $5.31.
A sum of 12054914 shares traded at recent session while its average daily volume was at 1.78M shares. Arcutis Biotherapeutics Inc shares reached a high of $25.75 and dropped to a low of $22.0 until finishing in the latest session at $24.95.
The one-year ARQT stock forecast points to a potential upside of 8.88. The average equity rating for ARQT stock is currently 1.25, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Arcutis Biotherapeutics Inc [ARQT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $27.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 25, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 30, 2024, representing the official price target for Arcutis Biotherapeutics Inc stock. Previously, the target price had yet another raise to $15, while Jefferies analysts kept a Buy rating on ARQT stock. On January 03, 2024, analysts increased their price target for ARQT shares from 4 to 8.
The Price to Book ratio for the last quarter was 21.51, with the Price to Cash per share for the same quarter was set at 1.59.
ARQT Stock Performance Analysis:
Arcutis Biotherapeutics Inc [ARQT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.88. With this latest performance, ARQT shares gained by 34.00% in over the last four-week period, additionally plugging by 69.15% over the last 6 months – not to mention a rise of 79.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 73.21, with the RSI for the last a single of trading hit 1.46, and the three-weeks RSI is set at 1.15 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 18.36, while it was recorded at 20.92 for the last single week of trading, and 15.24 for the last 200 days.
Insight into Arcutis Biotherapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Arcutis Biotherapeutics Inc [ARQT] shares currently have an operating margin of -32.58% and a Gross Margin at 89.10%. Arcutis Biotherapeutics Inc’s Net Margin is presently recorded at -35.40%.
Arcutis Biotherapeutics Inc (ARQT) Capital Structure & Debt Analysis
According to recent financial data for Arcutis Biotherapeutics Inc. ( ARQT), the Return on Equity (ROE) stands at -57.33%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -23.40%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Arcutis Biotherapeutics Inc’s Return on Invested Capital (ROIC) is -37.59%, showcasing its effectiveness in deploying capital for earnings.
Arcutis Biotherapeutics Inc (ARQT) Efficiency & Liquidity Metrics
Based on Arcutis Biotherapeutics Inc’s (ARQT) latest financial statements, the Debt-to-Equity Ratio is 0.79%, indicating its reliance on debt financing relative to shareholder equity.
Arcutis Biotherapeutics Inc (ARQT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Arcutis Biotherapeutics Inc. (ARQT) effectively leverages its workforce, generating an average of -$272719.3 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.20% and a Quick Ratio of 3.04%, indicating strong ability to cover short-term liabilities.
ARQT Stock EPS
With the latest financial reports released by the company, Arcutis Biotherapeutics Inc posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.17. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARQT.
Arcutis Biotherapeutics Inc [ARQT] Institutonal Ownership Details
There are presently around $112.73%, or 114.86%% of ARQT stock, in the hands of institutional investors. The top three institutional holders of ARQT stocks are: JENNISON ASSOCIATES LLC with ownership of 11.57 million shares, which is approximately 9.3712%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 10.0 million shares of the stock with an approximate value of $$93.04 million in ARQT stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$91.3 million in ARQT stock with ownership which is approximately 7.95%.
